mail
editor@ajptr.com
whatsapp
9409046853
logo

American Journal of PharmTech Research

Ankur Bhardwaj

Author Profile
Punjab Technical University, Kapurthala, India
2
Publications
2
Years Active
6
Collaborators
56
Citations

Publications by Ankur Bhardwaj

2 publications found • Active 2011-2015

2015

1 publication

RP-HPLC Method for Simultaneous Estimation of Free and Entrapped Isoniazid and Ciprofloxacin HCL in Lipid Polymer Hybrid Nanoparticles

with Saurav Bhandari, Ashish Chauhan, Amit Kumar Goyal, Abhinav Mehta
8/1/2015

Bioanalytical methods of Reverse Phase-High performance liquid chromatography (HPLC) was developed and validated for simultaneous estimation of Isoniazid (INH) and Ciprofloxacin Hydrochloride (CIP HCl) encapsulated in lipid polymeric hybrid nanoparticles (LPNs) in plasma and in organ homogenates of lung, liver, spleen and kidney of mice. Chromatographic separation was done using Agilent® C18 bonded silica column of dimensions 150 × 4.6 mm, 5μmwith flow rate 1.0 ml/min, injection volume 20 µland column temperature 40°C. The mobile phase consists of a mixture of 70 volumes of 0.1 percent v/v of trifluoroacetic acid(TFA) and 30 volumes of acetonitrile (ACN). The results indicated that the developed method was linear and selective for all matrices studied. Analysis of accuracy and precision showed adequate values, with relative standard deviation values lower than 5, which are in accordance with USFDA guidelines for bioanalytical method validation. Isoniazid (INH) and Ciprofloxacin Hydrochloride (CIP HCl) were stable in plasma and tissue homogenates under different storage and processing conditions. This method was applied to study the pharmacokinetic and biodistribution profile of both drugs in free form and in bound state with lipid nanoparticles. The results showed that polymeric nanoparticles showed higher drug accumulation in the target site i.e. lung as compared to non-target organs fulfilling our aim of developing a HPLC method for the simultaneous estimation of both drugs and their application in determination of pharmacokinetic and pharmacodynamic potential of the lipid nanoparticles.

2011

1 publication

COLLOIDAL DRUG DELIVERY SYSTEMS: A FUTURE PROSPECTIVE FOR TREATMENT OF TUBERCULOSIS

with Lalit Kumar, Veenu
10/1/2011

  Colloidal Drug Delivery system is an advancing technology expected to bring revolutionary changes in the field of pharma and health sciences including drug delivery, diagnostics and treatment. The advancement in colloidal drug delivery systems helps in preparing newer formulations which become useful for treatment of tuberculosis. Development of Metered dose inhaler (MDT) and Directly Observed Therapy (DOTS) also proves to helpful in treatment of tuberculosis. Various colloidal drug delivery systems liposomes, niosomes, nanoparticles and microparticles proves to be a successful tool for tuberculosis treatment. One of the preparations like microemulsions results in theimprovement of bioavailability of the drugs. Similarly corticosteroids also found to be an interesting tool here because corticosteroids reduced the risk of pleural thickening in tuberculosis patients. These various colloidal drug delivery systems minimize the problems of conventional therapy like poor penetration, drug resistance, systemic toxicity and also main the improved drug delivery. This article describes the applications of various formulations along with their future aspects in treatment of tuberculosis.  

Author Statistics
Total Publications:2
Years Active:2
First Publication:2011
Latest Publication:2015
Collaborators:6
Citations:56
Whatsapp